Skip to main content
TipRanks
Go Ultimate75% OFF

Nolato AB (NOLA.B) AI Stock Analysis

3 Followers
SE:NOLA.B

Nolato AB

(Nasdaq OMX AB:NOLA.B)

Select Model
Rating:65Neutral
Price Target:SEK 55.00â–²(4.36% Upside)
Action:downgraded
Date:11/05/26

Robust financials with minimal leverage and reliable cash generation form the primary support, reinforced by positive earnings call developments in medical solutions. Weak technical momentum from low RSI and negative MACD is the main drag on the overall score.

Positive Factors
Medical platform expansionThe acquisitions expand Nolato’s medical capabilities, geographic reach, and ability to deliver complete products rather than individual components. This can deepen customer relationships, support higher-value development work, and create a stronger platform for recurring medical manufacturing growth over the next several quarters.
Negative Factors
Medical margin pressureOngoing ramp-up costs reduce the earnings contribution from Nolato’s fastest-growing business and show that revenue growth is not yet converting fully into profit. Since larger projects are expected to ramp for several more quarters, margin recovery may remain gradual and execution dependent.

Nolato AB (NOLA.B) vs. iShares MSCI Sweden ETF (EWD)

-20%-10%0%10%20%SE:NOLA.B-5.88%EWD+15.64%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 1.33B
Dividend Yield
3.23%
Average Volume (3M)
222.81K
Price to Earnings (P/E)
21.1
Beta (1Y)
0.69
Revenue Growth
0.11%
EPS Growth
-14.70%
Country
Sweden
Employees
5,692
Sector
Healthcare
Sector Strength
51
Industry
Industrial - Specialties

Nolato AB Business Overview & Revenue Model

Company Description

Nolato AB (publ) is a Swedish enterprise that specializes in the creation, manufacturing, and commercialization of polymer-based products, utilizing plastics, silicones, and thermoplastic elastomers. Its extensive portfolio serves a diverse array of...

How the Company Makes Money

Nolato makes money mainly by acting as a contract manufacturer and development partner, earning revenue from producing and supplying customer-specific polymer components, subassemblies, and finished products. Its core revenue streams typically includ...

Nolato AB Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:-7.38%|Next Earnings Date:Feb 08, 2027
Earnings Call SentimentPositive

The call was broadly positive, with 15 highlights versus 11 lowlights. Nolato reported group sales growth, strong Medical Solutions and Materials performance, strategic acquisitions, improved operating cash flow, and a strong financial position. These positives were moderated by lower group and business-area margins, continued medical ramp-up costs, automotive weakness expected to persist in Q4, lower Hygiene volumes, and elevated intragroup costs.

Positive Updates

Group Sales Growth
Third-quarter sales rose 7% to SEK 2.5 billion from SEK 2.342 billion last year. Excluding currency effects and the two acquisitions, growth was 3%.

Negative Updates

Lower Operating Profit and Group Margin
Operating profit was SEK 254 million compared with SEK 281 million last year. On an adjusted basis, operating profit was SEK 262 million compared with SEK 274 million last year, while the adjusted group margin was 10.5% compared with 11.7% last year.

Company Guidance

For full year 2026, CapEx is expected to be SEK 600 million to SEK 650 million; the effective tax rate is normalized to around 23%; no headwind is expected in Q4 from raw material pricing if the present situation is remaining; the ramp-up of larger projects is expected to continue going forward some quarters, but is expected to be getting better and better; the automotive headwind will remain in the fourth quarter, while how it looks further on remains uncertain; and the ongoing rate for costs outside the business areas is expected to be somewhere in between the SEK 9 million and the SEK 15 million per quarter.

Nolato AB Financial Statement Overview

Summary

Strong balance sheet with very low debt-to-equity of 0.13 and solid operating cash flow of 1.15 billion underpin stability, though multi-year revenue decline limits top-line momentum.

Income Statement

64Positive

Balance Sheet

91Very Positive

Cash Flow

73Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue9.58B9.46B9.66B9.55B10.77B11.61B
Gross Profit1.74B1.73B1.61B1.34B1.43B1.82B
EBITDA1.37B1.59B1.51B1.28B1.48B1.92B
Net Income673.00M777.00M658.00M435.00M697.00M1.16B
Balance Sheet
Total Assets11.18B9.28B9.69B9.30B10.01B10.05B
Cash, Cash Equivalents and Short-Term Investments584.00M482.00M672.00M688.00M1.01B1.45B
Total Debt749.00M1.45B1.53B1.88B2.03B1.79B
Total Liabilities5.21B3.75B3.95B4.13B4.62B5.29B
Stockholders Equity5.97B5.53B5.74B5.17B5.39B4.77B
Cash Flow
Free Cash Flow752.00M278.00M742.00M355.00M-49.00M446.00M
Operating Cash Flow1.15B1.06B1.38B781.00M406.00M1.23B
Investing Cash Flow-1.13B-788.00M-636.00M-444.00M-451.00M-782.00M
Financing Cash Flow-15.00M-390.00M-798.00M-631.00M-487.00M-634.00M

Nolato AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price52.70

Price Trends

50DMA54.19Negative
100DMA52.11Positive
200DMA50.60Positive

Market Momentum

MACD-0.76Positive
RSI44.36Neutral
STOCH82.05Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NOLA.B, the sentiment is Neutral. The current price of 52.70 is below the 20-day moving average (MA) of 53.85, below the 50-day MA of 54.19, and above the 200-day MA of 50.60, indicating a neutral trend. The MACD of -0.76 indicates Positive momentum. The RSI at 44.36 is Neutral, neither overbought nor oversold. The STOCH value of 82.05 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:NOLA.B.

Nolato AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:NOLA.B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:LIFCO.BSE:LIFCO.B75OutperformSEK 131.90B33.5319.26%0.93%7.11%10.47%
SE:ALIF.BSE:ALIF.B74OutperformSEK 22.21B34.6211.32%0.82%1.62%63.45%
SE:ARJO.BSE:ARJO.B69NeutralSEK 9.96B27.494.65%2.60%-0.50%-17.58%
SE:NOLA.BSE:NOLA.B65NeutralSEK 14.20B21.0811.69%3.23%0.11%-14.70%
SE:XVIVOSE:XVIVO64NeutralSEK 6.49B50.375.89%―17.83%330.94%
SE:BERG.BSE:BERG.B61NeutralSEK 6.92B26.2813.53%1.61%1.00%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-25%0%25%50%75%SE:NOLA.BSE:LIFCO.BSE:ALIF.BSE:ARJO.BSE:XVIVOSE:BERG.BDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:NOLA.B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:NOLA.BNolato AB Class B52.70-4.16-7.32%
SE:LIFCO.BLifco Ab290.40-54.51-15.80%
SE:ALIF.BAddLife AB Class B182.103.652.05%
SE:ARJO.BArjo AB Class B36.567.0123.72%
SE:XVIVOXvivo Perfusion AB206.0042.5025.99%
SE:BERG.BBergman & Beving AB Class B261.00-40.38-13.40%

Nolato AB Corporate Events

Nolato lifts sales on Medtech strength but margins tighten amid higher costs

Oct 29, 2026

Nolato reported third-quarter 2026 sales of SEK 2.5 billion, up 7% year-on-year, with organic growth of 3% in a challenging market but a lower EBITA margin of 10.2% due to higher input costs. For the first nine months, sales edged up to SEK 7.3 billi...

Nolato Sets October 29 Webcast for Q3 2026 Interim Report

Oct 22, 2026

Nolato AB will release its interim report for the third quarter of 2026 on Thursday, October 29, at 7:45 a.m. CET, followed by an English-language webcast conference call at 8:45 a.m. CET led by President and CEO Anders Björklund and CFO Per-Ola Holm...

Nolato names Cecilia Hellner to lead Engineered Solutions

Oct 12, 2026

Nolato has appointed Cecilia Hellner as Head of the Engineered Solutions business area and a member of Group Management, following a recruitment process initiated after former area head Anders Björklund became President and CEO. Hellner, currently Ma...

Nolato sharpens portfolio with medtech acquisitions and Romanian exit

Oct 2, 2026

Nolato is accelerating its push into electronics-intensive medical technology and advanced manufacturing through the acquisitions of Unitron and M&M Qualtech, while simultaneously exiting its Romanian operation. These moves expand the group’s capabil...

Nolato boosts Medical Solutions arm with acquisition of Dutch CDMO Unitron

Sep 1, 2026

Nolato AB has agreed to acquire Dutch medical technology CDMO Unitron, an innovator with over 30 years’ experience and annual sales of around SEK 200 million, in a move that broadens its Medical Solutions business. Unitron, which operates in the Neth...

Nolato boosts electronics capacity with acquisition of Ireland’s M&M Qualtech

Aug 10, 2026

Nolato AB has agreed to acquire Irish electronics specialist M&M Qualtech, a Galway-based company with around 200 employees and estimated annual sales of approximately SEK 385 million in 2026, financed through Nolato’s own cash and existing credit fa...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026